FDG-PET to monitor early response to infliximab in refractory systemic sarcoidosis

Respiratory Medicine Extra Pub Date : 2007-01-01 DOI:10.1016/j.rmedx.2007.09.004

Alexandra Desvignes , Stéphane Zuily , Leilah Saadi , Pierre Olivier , Denis Regent , Hélène Schuhmacher , Denis Wahl

{"title":"FDG-PET to monitor early response to infliximab in refractory systemic sarcoidosis","authors":"Alexandra Desvignes , Stéphane Zuily , Leilah Saadi , Pierre Olivier , Denis Regent , Hélène Schuhmacher , Denis Wahl","doi":"10.1016/j.rmedx.2007.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Systemic sarcoidosis can result in dramatic manifestations despite therapeutic escalation. </span>Tumor necrosis factor (TNFα) has a key role in this disease and antagonists of TNFα have been successfully used as an alternative to conventional therapy. We report a case of refractory sarcoidosis with mediastinal, bone and ear, nose, throat (ENT) lesions.</p></div><div><h3>Methods</h3><p><span><span>In this patient we monitored response to treatment by infusions of the anti-TNFα antibody, </span>infliximab, with fluorine 18-fluorodeoxyglucose </span>positron emission tomography (FDG-PET).</p></div><div><h3>Results</h3><p>Early and spectacular response to infliximab was demonstrated by FDG-PET, which evidenced complete response to treatment.</p></div><div><h3>Conclusion</h3><p>This case supports use of FDG-PET to evaluate the extent of active disease in refractory sarcoidosis and above all, FDG-PET could be an imaging method of choice showing response to infliximab in refractory sarcoidosis earlier than other imaging techniques.</p></div>","PeriodicalId":101082,"journal":{"name":"Respiratory Medicine Extra","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedx.2007.09.004","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Extra","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1744904907000537","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Background

Systemic sarcoidosis can result in dramatic manifestations despite therapeutic escalation. Tumor necrosis factor (TNFα) has a key role in this disease and antagonists of TNFα have been successfully used as an alternative to conventional therapy. We report a case of refractory sarcoidosis with mediastinal, bone and ear, nose, throat (ENT) lesions.

Methods

In this patient we monitored response to treatment by infusions of the anti-TNFα antibody, infliximab, with fluorine 18-fluorodeoxyglucose positron emission tomography (FDG-PET).

Results

Early and spectacular response to infliximab was demonstrated by FDG-PET, which evidenced complete response to treatment.

Conclusion

This case supports use of FDG-PET to evaluate the extent of active disease in refractory sarcoidosis and above all, FDG-PET could be an imaging method of choice showing response to infliximab in refractory sarcoidosis earlier than other imaging techniques.

查看原文本刊更多论文

FDG-PET监测难治性系统性结节病对英夫利昔单抗的早期反应

背景:系统性结节病可导致戏剧性的表现，尽管治疗升级。肿瘤坏死因子(TNFα)在该疾病中起关键作用，TNFα拮抗剂已成功用于替代常规治疗。我们报告一例难治性结节病与纵隔，骨和耳，鼻，喉(耳鼻喉)病变。方法采用氟18-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)监测患者输注抗tnf α抗体英夫利昔单抗治疗的反应。结果FDG-PET显示对英夫利昔单抗的早期和显著的反应，证明对治疗完全缓解。结论本病例支持使用FDG-PET评估顽固性结节病活动性疾病的程度，最重要的是，FDG-PET可以作为一种首选的影像学方法，比其他影像学技术更早显示英夫利昔单抗对顽固性结节病的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respiratory Medicine Extra

自引率

0.00%

发文量